A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

NCT04776629 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Inflammation
Coronary Artery Disease
Cardiometabolic Syndrome

Interventions

DRUG: Orticumab
DRUG: Placebo

Sponsor

Abcentra